RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041